Verona Pharma to Present at Upcoming Healthcare Investor Conferences
LONDON, March 15, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (VRP.L) (VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announced that Company management will present at three upcoming investor conferences:
Event: 28th Annual Oppenheimer Healthcare Conference
Date: March 21, 2018
Time: 3:55 PM EDT
Location: New York, NY
Event: Needham & Co. Annual Healthcare Conference
Date: March 27, 2018
Time: 12:15 PM EDT
Location: New York, NY
Event: H.C. Wainwright Global Life Sciences Conference
Date: April 9, 2018
Time: 2:35 PM CEST
Location: Monte Carlo, Monaco
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma`s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo, and has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.
For further information, please contact:
Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer
Tel: +44 (0)20 3283 4200
info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
Tel: +44 (0) 20 7710 7600
SNELVeronaPharma@stifel.com
FTI Consulting (UK Media and Investor enquiries)
Simon Conway / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Verona Pharma plc via GlobeNewswire
HUG#2176622
